Tetraphase Pharmaceuticals, Inc.
(NASDAQ : TTPH)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
-2.56%19.152.0%$600.77m
SHPGShire PLC Sponsored ADR
1.04%172.180.4%$144.03m
GWPHGW Pharmaceuticals PLC Sponsored ADR
0.65%144.256.8%$132.66m
PRGOPerrigo Co. Plc
1.92%71.516.8%$92.51m
JAZZJazz Pharmaceuticals Plc
-1.40%156.602.2%$64.20m
ENDPEndo International Plc
0.69%17.638.9%$59.40m
MNKMallinckrodt Plc
0.44%27.2821.1%$58.05m
SAGESAGE Therapeutics, Inc.
-2.06%122.269.6%$47.01m
ICPTIntercept Pharmaceuticals, Inc.
-2.47%101.1718.7%$46.46m
UTHRUnited Therapeutics Corporation
0.38%123.5814.4%$35.04m
CTLTCatalent Inc
0.19%41.552.4%$32.44m
ICLRICON Plc
-0.85%143.704.1%$31.54m
PCRXPacira Pharmaceuticals, Inc.
2.37%45.1910.6%$25.67m
AERIAerie Pharmaceuticals, Inc.
0.88%55.866.9%$25.44m
MDCOMedicines Company
1.68%26.6721.8%$25.23m

Company Profile

Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.